Sanofi (SNY)
After hours:
| Previous Close | 54.92 |
| Open | 54.01 |
| Bid | 54.51 x 200 |
| Ask | 54.56 x 600 |
| Day's Range | 53.84 - 54.93 |
| 52 Week Range | 42.63 - 58.97 |
| Volume | |
| Avg. Volume | 1,803,034 |
| Market Cap | 136.816B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 29.66 |
| EPS (TTM) | 1.84 |
| Earnings Date | Oct 25, 2024 |
| Forward Dividend & Yield | 2.04 (3.71%) |
| Ex-Dividend Date | May 09, 2024 |
| 1y Target Est | 62.69 |
GlobeNewswireSanofi: Information concerning the total number of voting rights and shares - September 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of 2,537,214,304 €Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Regi
ReutersFrance considering stake in Sanofi's Opella, minister says
France is considering taking a stake in Sanofi's Opella arm, said finance minister Antoine Armand, to allay concerns that the French drugmaker's plans to sell a 50% stake in Opella to a U.S. private equity firm could result in job cuts. Trade unions and opposition politicians have expressed unease over Sanofi's decision to sell a controlling 50% stake in Opella - whose brands include painkiller Doliprane - to U.S. private equity firm Clayton Dubilier & Rice.
The Guardian‘The UK is at the back of the race of turtles’: Sanofi’s boss on the need to develop new medicines
Paul Hudson, the Briton in charge of the French drug firm, is a big believer in the potential of AI to transform healthcare
